Evercore ISI Initiates Revolution Medicines (RVMD) With an Outperform Rating – Here’s Why

Company Overview - Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company focused on developing novel targeted therapies for cancer treatment [4] Investment Potential - Revolution Medicines has been initiated with an Outperform rating and a price target of $140 by Evercore ISI, indicating strong buy potential [1] - The company is expected to launch daraxonrasib, which is seen as a potential breakthrough in oncology, with key Phase 3 data for pancreatic cancer anticipated in the first half of 2026 [1] Financial Performance - As of December 31, 2025, Revolution Medicines reported cash, cash equivalents, and marketable securities totaling $2.0 billion [2] - Research and development expenses for Q4 were $294.9 million, up from $188.1 million in the previous year, attributed to increased clinical trial and manufacturing costs for daraxonrasib, zoldonrasib, and elironrasib, as well as higher personnel-related expenses [3]